Search for a clinical trial
Other search option(s)
55 Result(s)
Recruiting trial
= 
; Ongoing trial
= 
; Terminated trial = 
; Funded by an IRDiRC member = 
; Study involving ERN members in at least two Member States = 
National clinical trial(s)
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
ADAPT NXT: A Phase 3b, Randomized, Open-label, Parallel-Group Study to Evaluate Different Dosing Regimens of Intravenous Efgartigimod to Maximize and Maintain Clinical Benefit in Patients With Generalized Myasthenia Gravis (gMG) - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
ADAPT JR: Open-label Uncontrolled Trial to Evaluate Pharmacokinetics, Pharmacodynamics, Safety, and Activity of Efgartigimod in Children From 2 to Less Than 18 Years of Age With Generalized Myasthenia Gravis - AT
Institution: Information not provided - AT
BELGIUM
ANTWERPEN
EDEGEM (ANTWERPEN)
NIMBLE: Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Symptomatic Generalized Myasthenia Gravis - BE
Antwerp University Hospital - UZA
Neuromusculair Referentiecentrum (NMRC) - UZ Antwerpen
BELGIUM
VLAAMS BRABANT
LEUVEN
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of lGIV-C as a Corticosteroid Sparing Agent in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis- BE
UZ Leuven - Campus Gasthuisberg
UZ Leuven
CANADA
Québec
ADDRESS: NOT PROVIDED - CA
An Open-Label Uncontrolled Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Activity of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis -CA
Institution: Information not provided - CA
FRANCE
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
Phase II, single arm, non-randomized and multicenter clinical trial of regorafenib as a single agent in the first-line
Institution: Information not provided - FR
FRANCE
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
NIMBLE: Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Symptomatic Generalized Myasthenia Gravis -FR
Institution: Information not provided - FR
FRANCE
ILE-DE-FRANCE
GARCHES
Comparison of Two Tapering Strategies of Prednisone in Patients With Generalised Myasthenia Gravis Treated With Prednisone and Azathioprine: a Single-blind Randomised Controlled Multicenter Study (Phase IV)
CHU Paris IdF Ouest - Hôpital Raymond Poincaré
Service de réanimation médico-chirurgicale adulte
FRANCE
OCCITANIE
TOULOUSE
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of lGIV-C as a Corticosteroid Sparing Agent in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis (Phase II) - FR
CHU de Toulouse - Hôpital Purpan
Département de neurologie
GERMANY
Berlin
ADDRESS: NOT PROVIDED - DE
A Randomized, Double-blind, Multicenter, Placebo-controlled Phase 3 Study With Open-label Period to Evaluate the Efficacy and Safety of Inebilizumab in Adults With Myasthenia Gravis -DE
Institution: Information not provided - DE
GERMANY
Nordrhein-Westfalen
ESSEN
ADAPT JR: Open-label Uncontrolled Trial to Evaluate Pharmacokinetics, Pharmacodynamics, Safety, and Activity of Efgartigimod in Children From 2 to Less Than 18 Years of Age With Generalized Myasthenia Gravis-DE
Universitätsklinikum Essen
Klinik für Kinderheilkunde I - Bereich Neuropädiatrie und SPZ
GERMANY
Sachsen
LEIPZIG
NIMBLE: Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients with Symptomatic Generalized Myasthenia Gravis -DE
Zentrum für Seltene Erkrankungen Leipzig
UZSEL - Universitäres Zentrum für Seltene Erkrankungen Leipzig
JAPAN
JAPAN
ADDRESS : NOT PROVIDED - JP
A Randomized, Double-Blind, Multicenter, Placebo-Controlled Phase 3 Study with Open-Label Period to Evaluate the Efficacy and Safety of Inebilizumab in Adults with Myasthenia Gravis (VIB0551.P3.S1)
Institution: Information not provided - JP
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
A randomized, double-blind, multicenter, placebo-controlled phase 3 study with open-label period to evaluate the efficacy and safety of inebilizumab in adults with myasthenia gravis -ES
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
An Open-Label Extension Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis -ES
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
ADAPT SC+: A Long-Term, Single-Arm, Open-label, Multicenter Phase 3 Study to Evaluate the Safety and Tolerability of Multiple Subcutaneous Injections of Efgartigimod PH20 SC in Patients With Generalized Myasthenia Gravis -ES
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
A phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate efficacy, safety, pharmacokinetics, and pharmacodynamics of satralizumab in patients with generalized myasthenia gravis - ES
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Nipocalimab Administered to Adults with Generalized Myasthenia Gravis -ES
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
ADAPT JR: Open-label Uncontrolled Trial to Evaluate Pharmacokinetics, Pharmacodynamics, Safety, and Activity of Efgartigimod in Children From 2 to Less Than 18 Years of Age With Generalized Myasthenia Gravis -ES
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
ADAPT NXT: A Phase 3b, Randomized, Open-label, Parallel-Group Study to Evaluate Different Dosing Regimens of Intravenous Efgartigimod to Maximize and Maintain Clinical Benefit in Patients With Generalized Myasthenia Gravis (gMG) -ES
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
NIMBLE: Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients with Symptomatic Generalized Myasthenia Gravis -ES
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults with Generalized Myasthenia Gravis - ES
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 3, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants with Generalized Myasthenia Gravis (gMG) - ES
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 3, Open-label, Single-arm, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants (6 to < 18 years of age) with Generalized Myasthenia Gravis (gMG) -ES
Institution: Information not provided - ES
UNITED STATES
Connecticut
CHESHIRE
ECU-MG-302, A Phase III, Open-label, Extension Trial of ECU-MG-301 to Evaluate the Safety and Efficacy of Eculizumab in Subjects With Refractory Generalized Myasthenia Gravis (gMG) (Phase III) - FR
Alexion Pharmaceuticals, Inc.
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naïve Adult Patients With Generalized Myasthenia Gravis - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
ADAPT JR.+ : A Long-term, Single-Arm, Open-label, Multicenter, Follow-on Trial of ARGX113-2006 to Evaluate Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis - AT
Institution: Information not provided - AT
GERMANY
Berlin
ADDRESS: NOT PROVIDED - DE
RAISE-XT: A Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia Gravis - DE
Institution: Information not provided - DE
ITALY
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
A Phase 2, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of TAK-079 in Patients With Generalized Myasthenia Gravis - IT
Institution: Information not provided - IT
ITALY
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
RAISE: A Phase 3, Multicenter, Randomized, Double Blind, Placebo-Controlled Study to Confirm the Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis - IT
Institution: Information not provided - IT
ITALY
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
RAISE-XT: A Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia Gravis - IT
Institution: Information not provided - IT
ITALY
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
A Phase 3, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of tolebrutinib (SAR442168) in adults with generalized myasthenia gravis (MG) - IT
Institution: Information not provided - IT
SPAIN
Comunidad Valenciana
VALENCIA
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naïve Adult Patients With Generalized Myasthenia Gravis -ES
Hospital Universitario y Politécnico La Fe
Servicio de Neurología
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia Gravis -ES
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants with Generalized Myasthenia Gravis -ES
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
ADAPT JR.+ : A Long-term, Single-Arm, Open-label, Multicenter, Follow-on Trial of ARGX113-2006 to Evaluate Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis - ES
Institution: Information not provided - ES
SWEDEN
Region Stockholm
SOLNA
Rinomax - A clinical trial investigating the effect and safety of the drug rituximab in patients with new onset myasthenia gravis, an autoimmune condition affecting muscle strenght - SE
Karolinska Institutet
Department of Clinical Neuroscience (CNS)
FRANCE
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
Efficacy and safety evaluation of the ExoMS exoskeleton: an innovative impressed 3D upper limb assistive device for children with neuromuscular diseases. A Single-Case Experimental Design trial using Goal Attainment Scaling.
Institution: Information not provided - FR
JAPAN
JAPAN
ADDRESS : NOT PROVIDED - JP
Multicenter cooperative and investigator initiated clinical trial using valproic acid in childhood onset spinal muscular atrophy : Confirmatory Trial
Institution: Information not provided - JP
Multinational clinical trial(s)
BELGIUM
OOST-VLAANDEREN
GENT
FRANCE
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
URSA: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Tolebrutinib (SAR442168) in Adults With Generalized Myasthenia Gravis (MG).
Institution: Information not provided - FR
SWITZERLAND
Suisse Romande
ADDRESS: NOT PROVIDED - CH
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SATRALIZUMAB IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS
Institution: Information not provided - CH
UNITED STATES
Maryland
GAITHERSBURG
UNITED STATES
Massachusetts
CAMBRIDGE
An Open-label Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients With Generalized Myasthenia Gravis
Momenta Pharmaceuticals, Inc.
UNITED STATES
Washington
ADDRESS: NOT PROVIDED - US
A Phase III, Open-label, Extension Trial of ECU-MG-301 to Evaluate the Safety and Efficacy of Eculizumab in Subjects With Refractory Generalized Myasthenia Gravis (gMG)
Institution: Information not provided - US
UNITED STATES
Washington
ADDRESS: NOT PROVIDED - US
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of lGIV-C as a Corticosteroid Sparing Agent in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis
Institution: Information not provided - US
UNITED STATES
Washington
ADDRESS: NOT PROVIDED - US
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in Symptomatic Subjects With Generalized Myasthenia Gravis
Institution: Information not provided - US
UNITED STATES
Washington
ADDRESS: NOT PROVIDED - US
An Open-Label Uncontrolled Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Activity of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis.
Institution: Information not provided - US
UNITED STATES
Washington
ADDRESS: NOT PROVIDED - US
NIMBLE: Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Symptomatic Generalized Myasthenia Gravis.
Institution: Information not provided - US
BELGIUM
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis
UCB Biopharma SPRL
UNITED KINGDOM
Greater London
LONDON
A Phase 2, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of TAK-079 in Patients With Generalized Myasthenia Gravis
Takeda Development Centre Europe Ltd.
UNITED STATES
Connecticut
CHESHIRE
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naïve Adult Patients With Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.
UNITED STATES
Massachusetts
CAMBRIDGE
RAISE-XT: A Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia Gravis
Ra Pharmaceuticals, Inc.
UNITED STATES
Massachusetts
CAMBRIDGE
RAISE:A Phase 3, Multicenter, Randomized, Double Blind, Placebo-Controlled Study to Confirm the Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis
Ra Pharmaceuticals, Inc.
UNITED STATES
Washington
ADDRESS: NOT PROVIDED - US